Raltitrexed

• CAT Number: A000990
• CAS Number: 112887-68-0
• Molecular Formula: C21H22N4O6S
• Molecular Weight: 458.49
• Purity: ≥95%
• Synonyms: Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694
• Target: Cell Cycle/DNA Damage
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• InChI: 1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
• InChIKey: IVTVGDXNLFLDRM-HNNXBMFYSA-N
• SMILES: CC1=NC(=O)C2=C(N1)C=CC(=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O

Raltitrexed (Cat No.: A000990), also known as ZD 1694, is an antimetabolite drug used in treatment of colorectal cancer since 1998. It may also be used in the treatment of malignant mesothelioma. It is an inhibitor of thymidylate synthase, and is manufactured by AstraZeneca. Raltitrexed is a quinazoline folate analogue with antineoplastic activity. After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity.